Your search for esrd returned 65 results

Pfizer announced results from two of its Phase 3 studies, ORAL Standard and Oral Step, of tofacitinib (CP-690,550) for the treatment of active rheumatoid arthritis.

The labeling for Onglyza (saxagliptin; Bristol-Myers Squibb) has been updated to include data from two clinical trials: a study of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD) and a second comparator study of Onglyza + metformin versus glipizide + metformin.

BELLUS Health and Celtic Therapeutics announced that a global confirmatory Phase 3 study was initiated for their orphan status drug, Kiacta (eprodisate), for the treatment of Amyloid A (AA) amyloidosis.

Keryx announced results from its Phase 3 trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

Keryx Biopharmaceuticals announced results from the Phase 2 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis.